Last updated on April 2018

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Brief description of study

This is an experimental research study and does not constitute treatment or therapy. INCB059872 is an investigational drug that is being studied by Incyte Corporation (the “Sponsor” of the research study) for use in the treatment of Sickle Cell Disease.    

INCB059872 is a compound in the family of medications called LSD1 Inhibitors. There has been early research that shows that this class of drug may have potential to be effective treatment for Sickle Cell Disease once a safe and tolerable dose can be determined. 

The purposes of the Study are to:

  • determine how safe and well tolerated INCB059872 is
  • determine what the recommended dose of INCB059872 for patients with Sickle Cell Disease will be.
  • study how INCB059872 acts on and in your body 
  • study the way INCB059872 enters and leaves your body over time

Clinical Study Identifier: TX202590

Find a site near you

Start Over

Virginia Commonwealth University

730 East Broad Street, Suite 430 Richmond, VA USA
  Connect »